Alexion Pharmaceuticals (ALXN) Coverage Initiated by Analysts at Wedbush

Wedbush started coverage on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) in a research note published on Wednesday, BenzingaRatingsTable reports. The brokerage issued an outperform rating and a $173.00 price target on the biopharmaceutical company’s stock.

A number of other equities research analysts have also recently issued reports on the stock. Cowen reaffirmed a buy rating and issued a $165.00 price objective on shares of Alexion Pharmaceuticals in a research note on Wednesday, March 13th. Raymond James upped their price objective on shares of Alexion Pharmaceuticals from $161.00 to $164.00 and gave the company an outperform rating in a research note on Friday, April 26th. Credit Suisse Group reissued a buy rating and set a $156.00 price target on shares of Alexion Pharmaceuticals in a research report on Tuesday, January 22nd. Morgan Stanley increased their price target on shares of Alexion Pharmaceuticals from $165.00 to $175.00 and gave the company an overweight rating in a research report on Tuesday, February 12th. Finally, Guggenheim reissued a neutral rating and set a $135.00 price target on shares of Alexion Pharmaceuticals in a research report on Thursday, March 21st. Seven research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus target price of $161.06.

Shares of Alexion Pharmaceuticals stock opened at $127.15 on Wednesday. Alexion Pharmaceuticals has a 52-week low of $92.56 and a 52-week high of $141.86. The firm has a market capitalization of $28.51 billion, a PE ratio of 17.93, a price-to-earnings-growth ratio of 1.01 and a beta of 1.53. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.87 and a quick ratio of 3.36.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.99 by $0.40. Alexion Pharmaceuticals had a net margin of 9.59% and a return on equity of 19.53%. The company had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.13 billion. During the same quarter in the prior year, the company earned $1.68 EPS. The firm’s revenue was up 22.5% on a year-over-year basis. As a group, equities research analysts forecast that Alexion Pharmaceuticals will post 8.6 EPS for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the business. FMR LLC raised its holdings in Alexion Pharmaceuticals by 10.4% in the 1st quarter. FMR LLC now owns 29,144,320 shares of the biopharmaceutical company’s stock worth $3,939,729,000 after purchasing an additional 2,746,055 shares in the last quarter. Vanguard Group Inc raised its holdings in Alexion Pharmaceuticals by 1.2% in the 3rd quarter. Vanguard Group Inc now owns 15,811,291 shares of the biopharmaceutical company’s stock worth $2,197,928,000 after purchasing an additional 192,857 shares in the last quarter. Jennison Associates LLC raised its holdings in Alexion Pharmaceuticals by 17.3% in the 1st quarter. Jennison Associates LLC now owns 10,241,457 shares of the biopharmaceutical company’s stock worth $1,384,440,000 after purchasing an additional 1,512,545 shares in the last quarter. Clearbridge Investments LLC raised its holdings in Alexion Pharmaceuticals by 12.9% in the 1st quarter. Clearbridge Investments LLC now owns 5,810,033 shares of the biopharmaceutical company’s stock worth $785,400,000 after purchasing an additional 665,574 shares in the last quarter. Finally, Artisan Partners Limited Partnership raised its holdings in Alexion Pharmaceuticals by 220.9% in the 1st quarter. Artisan Partners Limited Partnership now owns 4,248,248 shares of the biopharmaceutical company’s stock worth $574,278,000 after purchasing an additional 2,924,550 shares in the last quarter. 97.89% of the stock is owned by institutional investors and hedge funds.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

See Also: What is a short straddle?

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.